Physician
The Pain Management Clinic LLC
The Pain Management Clinic LLC was paid $1.59M by Medicaid between Jan 2018 and Oct 2021, across 45 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoTHE PAIN MANAGEMENT CLINIC LLC
CAMBRIDGE, OH 43725
CAMBRIDGE, OH 43725
33aNPI1750435905assigned 01/23/2007
33bProvider typePain Medicine (Anesthesiology) Physician
28Total paid$1.59M
24GClaims105,249
24DCodes billed45
24AFirst – last monthJan 2018 – Oct 2021
Compared with peers
Next to other Pain Medicine (Anesthesiology) Physician providers in Ohio
Rank by total paid#6 of 43
Median peer was paid$52K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,208 | $567K | |
| 2019 | 34,094 | $502K | |
| 2020 | 31,721 | $374K | |
| 2021 | 5,226 | $143K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 15,202 | 14,607 | $395K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 10% | 3,812 | 3,722 | $164K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.1% | 7,436 | 7,065 | $113K |
| 62323 | 4.2% | 624 | 588 | $66K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 4.0% | 1,436 | 1,393 | $63K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.3% | 391 | 388 | $53K |
| 80361 | 2.9% | 3,499 | 3,441 | $47K | |
| 80346 | 2.7% | 3,498 | 3,440 | $43K | |
| 80345 | 2.3% | 3,500 | 3,442 | $37K | |
| 80365 | 2.3% | 3,500 | 3,442 | $37K | |
| 80358 | 2.3% | 3,500 | 3,442 | $37K | |
| 80348 | 2.3% | 3,500 | 3,442 | $37K |
33 more codes
| 80359 | 2.3% | 3,499 | $37K | |
| 80366 | 2.3% | 3,498 | $37K | |
| 80371 | 2.3% | 3,497 | $36K | |
| 80368 | 2.3% | 3,497 | $36K | |
| 80369 | 2.3% | 3,497 | $36K | |
| 80372 | 2.3% | 3,497 | $36K | |
| 80373 | 2.3% | 3,498 | $36K | |
| 80349 | 2.3% | 3,477 | $36K | |
| 80356 | 2.3% | 3,477 | $36K | |
| 80324 | 2.3% | 3,476 | $36K | |
| 80353 | 2.3% | 3,477 | $36K | |
| 80354 | 2.3% | 3,477 | $36K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.3% | 305 | $21K |
| 99406 | <1% | 801 | $7K | |
| 80360 | <1% | 698 | $7K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 623 | $6K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 823 | $5K |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | <1% | 103 | $4K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 32 | $3K |
| 80306 | <1% | 242 | $3K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 412 | $2K |
| 80305 | <1% | 95 | $856.80 | |
| 20553 | <1% | 14 | $274.35 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 599 | $120.89 |
| E0730 | Transcutaneous electrical nerve stimulation (tens) device, four or more leads, for multiple nerve stimulation | <1% | 13 | $49.01 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | <1% | 2,923 | $7.48 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | <1% | 2,627 | $7.48 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 2,925 | $7.48 |
| G9367 | At least two orders for high-risk medications from the same drug class | 0% | 137 | $0.00 |
| G9459 | Currently a tobacco non-user | 0% | 47 | $0.00 |
| G9365 | One high-risk medication ordered | 0% | 39 | $0.00 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 13 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSAYEGH, MICHAEL (OWNER PHYSICIAN)
| Provider | Location | Paid |
|---|---|---|
| New York Cataract & Laser Eye Care PC | Yonkers, NY | $1.91M |
| Eastern Orange Ambulatory Surgery Center, LLC | Cornwall, NY | $48K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.